Edition:
United Kingdom

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

10.38USD
19 Oct 2018
Change (% chg)

$0.13 (+1.27%)
Prev Close
$10.25
Open
$10.25
Day's High
$10.46
Day's Low
$10.20
Volume
46,519
Avg. Vol
127,479
52-wk High
$12.35
52-wk Low
$3.37

Latest Key Developments (Source: Significant Developments)

Zafgen Announces Proposed Offering Of Common Stock
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Zafgen Inc ::ZAFGEN ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.  Full Article

Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount​ Of $20 Mln
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Zafgen Inc ::ZAFGEN SAYS ‍ON DEC 29, CO ENTERED INTO LOAN AND SECURITY AGREEMENT PROVIDING FOR TERM LOAN WITH PRINCIPAL AMOUNT​ OF $20 MILLION - SEC FILING.  Full Article

Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Zafgen Inc ::ZAFGEN REPORTS STRONG CLINICAL PROGRESS AND UPDATES OUTLOOK FOR 2018.ZAFGEN- INCREASED CASH POSITION DURING Q4, EXPECTS TO END CALENDAR YEAR 2017 WITH OVER $100 MILLION IN CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES.ZAFGEN INC - WELL-CAPITALIZED TO SUPPORT ITS CLINICAL-STAGE DEVELOPMENT PROGRAMS BEYOND FIRST HALF OF 2019.ZAFGEN - ‍ENTERED A $20 MILLION VENTURE DEBT FINANCING AGREEMENT WITH SILICON VALLEY BANK ON DEC 29, EXTENDING EXPECTED CASH RUNWAY BEYOND H1 2019​.ZAFGEN INC - TOPLINE DATA ARE EXPECTED IN MID-YEAR 2018 FOR ZGN-1258.ZAFGEN -FOR ZGN-1258,‍ BEGINNING IND APPLICATION-ENABLING WORK IN Q1 FOR FILING WITH U.S. FDA, BEGINNING PHASE 1 CLINICAL DEVELOPMENT BY END OF YEAR​.  Full Article

Zafgen reports Q3 loss per share $0.46
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Zafgen Inc :Zafgen reports third quarter 2017 financial results.Q3 loss per share $0.46.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Zafgen- continues to expect its cash, cash equivalents and marketable securities balance to be greater than $70 million as of december 31, 2017​.Zafgen Inc - ‍initiated phase 2 clinical trial for second generation metap2 inhibitor ZGN-1061​.  Full Article

Zafgen appoints Jeffrey Hatfield as CEO
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Zafgen Inc ::Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer.Zafgen Inc - Hatfield and Hughes will serve on Zafgen's board of directors​.  Full Article

BRIEF-Zafgen Reports Q1 Loss Per Share $0.58

* ZAFGEN REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS